

10/516079

FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006
=> Index biocci
FILE 'DRUGMONO2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
FULL ESTIMATED COST
INDEX 'ADISCTI', ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCII, BIOGEN, BIOSIS, BIOTCHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CN, CONFCII, CROB, CROPU, DDFU, DDFU, DGENE, DISSEAB,
DRUGMONO2, DRUGU, EMBAL, EMBASE, ... ENTERED AT 03:09:52 ON 09 JUN 2006
68 FILES IN THE FILE LIST IN STNINDEX
Enter SET DETAIL ON to see search term postings or to view
search error messages that display as * with SET DETAIL OFF.
=> 6 chlorotoxin
3 FILE ADISINSIGHT
5 FILE AGRICOLA
1 FILE ANABSTR
32 FILE BIOSIS
3 FILE BIOTCHABS
2 FILE BIOTECHDS
8 FILE BIOTECHNO
11 FILE CABA
41 FILE CAPLUS
1 FILE CEABA-VTB
8 FILE CIN
2 FILE DDFU
235 FILE DGENE
2 FILE DISSEAB
2 FILE DRUGU
28 FILE EMBASE
22 FILE ESBIOBASE
1 FILE GENBANK
13 FILE IFIPAT
9 FILE IMRDUGNEWS
5 FILE IMRESEARCH
13 FILE LIFESCI
31 FILE MEDLINE
17 FILE PASCAL
5 FILE PHAR
5 FILE PHIN
29 FILE PRONT
38 FILE SCISEARCH
68 FILE TOXCENTER
38 FILE USPATFULL
7 FILE USPAT2
64 FILES SEARCHED...
11 FILE WPIDS
11 FILE WINDEX
33 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX
L1 QUE CHLOROTOXIN
=> 6 11 and chenother?
1 FILE ADISINSIGHT
1 FILE BIOTECHNO
2 FILE CAPLUS
129 FILE DGENE
2 FILE EMBASE
2 FILE ESBIOBASE
1 FILE IFIPAT
1 FILE IMRDUGNEWS
1 FILE IMRESEARCH
1 FILE PRONT
1 FILE SCISEARCH
1 FILE TOXCENTER
1 FILE USPAT2
64 FILES SEARCHED...
11 FILE WPIDS
11 FILE WINDEX
33 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX
L2 QUE L1 AND CHEMOTHER?
=> b dgene caplus biotechno embase ifipat medline pront toxcenter uspatfull windex
wpids wpindex
COST IN U.S. DOLLARS
FULL ESTIMATED COST
FILE 'DGENE' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
FILE 'CAPLUS' ENTERED AT 03:12:00 ON 09 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOTECHNO' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'EMBASE' ENTERED AT 03:12:00 ON 09 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.
FILE 'ESBIOBASE' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'IFIPAT' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)
FILE 'MEDLINE' ENTERED AT 03:12:00 ON 09 JUN 2006
FILE 'PRONT' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Gale Group. All rights reserved.
FILE 'TOXCENTER' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 ACS
FILE 'USPAT1' ENTERED AT 03:12:00 ON 09 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 03:12:00 ON 09 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'WPIDS' ACCESS NOT AUTHORIZED
FILE 'WINDEX' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
=> s 12
L3 174 L2
=> dup remo
ENTER L# LIST OR (END) :13
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4 163 DUP REMO L3 (11 DUPLICATES REMOVED)

=> S 14 and (cisplatin or carboplatin or hydroxyurea or paclitaxel or temozolamide or topotecan or fluorouracil or vincristine or vinblastine or dacarbazine or docetaxane or altretamine) FILES SEARCHED...
 L5 9 L4 AND (BCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR
 PACLITAXEL OR TEMOZOLOMIDE OR TOPOTECAN OR FUJORUACIL OR VINCRI
 TINE OR VINBLASTINE OR PROCARBAZINE OR ALTRETTAMINE)
 L6 13 L4 AND (CIPERATIN OR METHOTREXATE OR MERCAPTOPURINE OR THIOGUANINE
 NE OR FUJUDARABINE OR CLADBINE OR PENTOSTATIN OR CITARABINE OR
 AZACTIDINE OR VINBLASTINE OR ETOPOSIDE OR TENIPOSIDE OR IRINOTEC
 AN)

=> S 14 and (doxorubicin or daunorubicin or idarubicin or idarubicin or plicamycin or mitomycin or bleomycin or tamoxifen or flutamide or leuprolide or goserelin or aminoglutethimide)
 L7 13 L4 AND (DOCTETAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOMYCI
 N OR IDARUBICIN OR Plicamycin OR MITOMICIN OR BLEOMYCIN OR TAXOM
 IFEN OR FLUTAMIDE OR LEUPROLIDS OR GOSERELIN OR AMINOGLUTETHIMIDE)

=> S 14 and (anastrozole or amsacrine or asparaginase or mitoxantrone or mitotane or amifostine)
 L8 7 L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARAGINASE OR MITOXANTRON
 E OR MITOTANE OR AMIFOSTINE)
 => S 15 and 16 and 17 and 18
 L9 6 L5 AND L6 AND L7 AND L8

=> d 19 1-6 bib abs
 L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 DN 143:1154420 CAPLUS
 143:132633
 TI Use of chlorotoxin in diagnosis and treatment of myeloid and
 lymphoid cell cancers
 IN Alvarez, Vernon L.; Gonda, Matthew A.
 PA Transmolecular, Inc., USA
 SO PCT Int. Appl., 52 pp
 CODEN: PIXKD2
 DT Patent
 LA English
 FAN CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2005099774 A2 20051027 WO 2005-0511523 20050406

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, EG, FI, GL, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NR,
 NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
 SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, VG, ZM, ZW, AM,
 AZ, BI, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, ME,

PRAI US 2004-554433P P 20040406

AB Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth. The chlorotoxin may be conjugated to a second protein,

e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific epitope, or a stabilizing protein such as human serum albumin. Alternatively, the chlorotoxin may be conjugated to a cytotoxic agent or chemotherapeutic agent.

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:1971507 CAPLUS

DN 140 : 23219
 TI Combination on chemotherapy with chlorotoxin for treating

cancer

IN Alvarez, Vernon L.; Grimes, Carol A.; Gonda, Matthew A.

PA Transmolecular, Inc., USA

SO PCT Int. Appl., 100 pp.

DT Patent

LA English

FAN CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101474 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GL, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TU, TM, TN, TR, TT, RW: GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, VG, ZM, ZW, AM, AZ, BY, RG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, CA, BE, BJ, CF, CG, CI, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG	A1	20031211	WO 2003-US174100	20030602
CA 2487445 AU 2003204956 EP 1553942 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, JP 200557234 T2 US 20060588899 P: US 2002-384171P P: US 2002-406033P WO 2003-US17410	AA	20031211	CA 2003-24874425	20030602
JP 20051208 A1	20050427	JP 2004-508829	20030602	
US 20060427 P: US 2005-516079 P: P: 20020827 W: 20030502		US 2005-516079	20051102	
AB This invention includes comp., and methods for combination chemotherapy, particularly involving at least one chemotheapeutic agent used in combination with chlorotoxin or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled chlorotoxin or chlorotoxin derivative are also claimed.				
RE CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE IN THE RE FORMAT				
L9 ANSWER 3 OF 6 IPIPAT COPYRIGHT 2006 IPI on STN				
AN 1113983: IPIPAT:IFIUDB:IFIICDB COMBINATION CHEMOTHERAPY WITH CHLOROTOXIN				
TI INF Alvarez, Vernon L., Birmingham, AL, US				
INF Gonda, Matthew A., Birmingham, AL, US				
IN Alvarez, Vernon L., Gonda, Matthew A.; Grimes, Carol A.				
PAT Unassigned Or Assigned To Individual (68000)				
PA MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, AG				
PI 20004, US US 2006088899 A1 20060427				
AI US 2003-516079 20030602				
WO 2003-US17410 20030602				
PCT 371 date 20051102				
PCT 102 (e) date 20051102				
PRAI US 2002-384171P 20020827 (Provisional)				
PAI US 2002-406033P 20020827 (Provisional)				
FI US 2006088899 20060427				

DT Utility; Patent Application - First Publication
FS APPLICATION
PARN This application claims the benefit of U.S. Provisional Application
60/406,033 (filed Aug. 27, 2002) and U.S. Provisional Application
60/384,171 (filed May 31, 2002) both of which are hereby incorporated by
reference in their entirety.

CLMN 17
OF 6 IPIPAT COPYRIGHT 2006 IFIP ON STN

AB This invention includes compositions and methods for combination
chemotherapy, particularly involving at least one
chemotherapeutic agent used in combination with
chlorotoxin or a derivative thereof.

CLMN 17

ANSWER 4 OF 6 USPATFULL ON STN
2005:334233 USPATFULL
PI-3 kinase inhibitor prodrugs
Garlich, Joseph R., Westfield, IN, UNITED STATES
Burden, Donald L., Decatur, GA, UNITED STATES
Patterson, Mary, Carmel, IN, UNITED STATES
Su, Jingdong, Westfield, IN, UNITED STATES
Suh, Robert G., Greenfield, IN, UNITED STATES
US 2005203173 AI 20050915 (11)
AI US 2005111201 AI 20050420 (11)
RJL Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING
PRJ US 2003-460137P DT Utility
FS APPLICATION LREP HOMERY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE
200 FALLS CHURCH, VA, 22042-2924, US
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRN 8 Drawing Page(s)
IN CNT 2648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The
novel compounds are LY294002 and analogs thereof comprising a reversibly
quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 6 USPATFULL ON STN
2005:105793 USPATFULL
V targeted delivery of nanoscale particles
Ivkov, Robert, Marblehead, MA, UNITED STATES
Dau, Wolfgang, Groton, MA, UNITED STATES
Foreman, Allian, Epping, NH, UNITED STATES
Gwest, Douglas, Shoreview, MN, UNITED STATES
Triton Biosystems, Inc., Chelmsford, MA, UNITED STATES (U.S.
corporation)
US 2005050732 AI 20050428
US 2005396339 AI 20031028 (10)
DT Utility
FS APPLICATION LREP PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET,
PITTSBURGH, PA, 15219, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1
DRN 12 Drawing Page(s)
IN CNT 2398
AB Disclosed are compositions, systems and methods for treating a subject's
body, body part, tissue, body fluid cells, pathogens, or other
undesirable matter involving the administration of a targeted
thermotherapy that comprises a bioprobe (energy susceptible materials
that are attached to a target-specific ligand). Such targeted therapy
methods can be combined with at least one other therapy technique. Other
therapies include hyperthermia, direct antibody therapy, radiation,
chemo- or pharmaceutical therapy, photodynamic therapy, surgical or

interventional therapy, bone marrow or stem cell transplantation, and
medical imaging, such as MRI, PET, SPECT, and bioimaging. The
disclosed therapies may be useful in the treatment of a variety of
indications, including but not limited to, cancer of any type, such as
bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate
cancer, epithelialized sarcomas, AIDS, adverse angiogenesis, restenosis,
amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque,
obesity, malaria, and illnesses due to viruses, such as HIV.

L9 ANSWER 6 OF 6 USPATFULL ON STN
2004:307935 USPATFULL
PI-3 kinase inhibitor prodrugs
Garlich, Joseph R., Westfield, IN, UNITED STATES
Burden, Donald L., Decatur, GA, UNITED STATES
Patterson, Mary, Carmel, IN, UNITED STATES
Su, Jingdong, Westfield, IN, UNITED STATES
Suh, Robert G., Greenfield, IN, UNITED STATES
US 2004244631 AI 20041202
US 6949537 B2 20050927
AI US 2004-818145 AI 20040405 (10)
PRJ US 2003-460137P DT Utility
FS APPLICATION LREP HOMERY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34,
1229 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRN 8 Drawing Page(s)
IN CNT 3032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The
novel compounds are LY294002 and analogs thereof comprising a reversibly
quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
=> d his

(FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCII, BIOENG, BIOSIS, BIOTECHNO, BIOTECHDS, BIOTECNO, CABA, CARLUS,
CEABA-VTB, CIN, CONFSCI, CROP, CROPY, DDFB, DDFU, DGENE, DISABS, DRUGS,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006
SEA CHLOROTOXIN

3 FILE ADISINSIGHT
5 FILE AGRICOLA
1 FILE ANABSTR
32 FILE BIOSIS
3 FILE BIOTECHDS
3 FILE BIOTECNO
8 FILE CABA
11 FILE CAPLUS
41 FILE CABA-VTB
1 FILE CEABA-VTB
8 FILE CIN
2 FILE DDFU
235 FILE DGENE
2 FILE DISABS
2 FILE DRUGU
28 FILE EMBASE
22 FILE ESBIOBASE
1 FILE GENBANK
13 FILE IFIPAT
9 FILE IMSDRUGNEWS
5 FILE IMRSEARCH

13 FILE LIFEESCI
 31 FILE MEDLINE
 17 FILE PASCAL
 5 FILE PHAR
 5 FILE PHIN
 29 FILE PRONT
 38 FILE SCISearch
 68 FILE TOXCENTER
 38 FILE USPATFULL
 7 FILE USPAT2
 11 FILE WPIIDS
 11 FILE WINDEX
 QUE CHLOROTOXIN
 SEA L1 AND CHEMOTHER?

QUE L1 AND CHEMOTHER?

1 FILE ADISINSIGHT
 1 FILE BIOTECHNO
 2 FILE CARLUS
 129 FILE DGENE
 2 FILE EMBASE
 2 FILE ESBIOBASE
 1 FILE IFIPAT
 1 FILE IMBDRUGNEWS
 1 FILE IMRERESEARCH
 1 FILE MEDLINE
 2 FILE PHAR
 1 FILE PHIN
 11 FILE PRONT
 3 FILE TOXCENTER
 16 FILE USPATFULL
 4 FILE USPAT2
 2 FILE WPIIDS
 2 FILE WINDEX

QUE L1 AND CHEMOTHER?

FILE 'DGENE, CAPLUS, BIOTECHNO, EMBASE, ESBIOBASE, IFIPAT, MEDLINE,
 PRONT, TOXCENTER, USPATFULL, WINDEX'. ENTERED AT 03:12:00 ON 09
 JUN 2006
 L3 174 S L2
 L4 163 DUP REMO L3 (11. DUPLICATES REMOVED)
 L5 9 AND (CNU OR CISPLATIN OR GEMCITABINE OR HYDROXYURACIL OR P
 L6 13 S L4 AND (COPPLANIN OR METHOTREXATE OR MERCAPTOPURINE OR THILOGU
 L7 13 S L4 AND (DOCTETAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOM
 L8 7 S L4 AND (MANASTROZOLE OR ASPARAGINASE OR MITOXANT
 L9 6 S L5 AND L6 AND L7 AND L8
 => d 15 1-9 bib abs

LS ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 200511154420 CAPLUS

DN 143:43233

TI Use of chlorotoxin in diagnosis and treatment of myeloid and
 lymphoid cell cancers L1: Gonda, Matthew A.

IN Alvarez, Vernon L.; Gonda, Matthew A.
 PA Transmolecular, Inc., USA
 SO PCT Int. Appl., 52 pp.

DT Patent

LA English
 FAN.CNT¹

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 200509974 R2 20051027 WO 2005-US11523 20050406

WO 200509974 A3 20060323 BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UR, US, VN, YU, ZA, ZM, RW: GH, GM, KE, LS, MN, ME, SD, SL, SZ, TZ, UG, ZH, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, CA, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TC AU 20031211 AA 20031211 CA 2003-248745 20030612 EP 1553962 A1 20031219 AU 2003-240496 20030612 EP 1553962 A1 20050720 EP 2003-731504 20030602 R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SR JP 2005537234 T2 20051028 JP 2004-508829 20030602 US 2006018899 A1 20060427 US 2005-516079 20051102 PRAI US 2002-384171P A1 20020531 P 20020827 WO 2003-46013P P 20030602 AB This invention includes compns. and methods for combination
 chemotherapy, particularly involving least one
 chemotherapeutic agent used in combination with
 chlorotoxin or a derivative thereof. A method for detecting the
 presence of cancer in a patient comprising administering a detectable amount
 of labeled chlorotoxin or chlorotoxin derivative are also
 claimed.

RE.CNT³ THERE ARE 3 CITED REFERENCES AVAILABLE IN THE RE FORMAT

LS ANSWER 3 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

AN 200227256 EMBASE

TI Orathecin is active in pancreatic cancer patients.

IC, IK, LR, LS, LT, LU, MA, MD, MG, MN, NW, MX, MZ, NA,
 NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SG, SK, SL,
 SM, SY, TJ, TM, TN, TR, TT, UG, US, UZ, VC, VN, YU, ZA,
 ZM, ZW
 RW: BW, GH, GM, KE, LS, MN, MZ, NA, SD, SL, SZ, TZ, US, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CX, CZ, DB, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML,
 MR, NE, SN, TD, TG
 PRAI US 2004-55943P P 20040406
 AB Disclosed is a method of diagnosing and treating myeloproliferative or
 lymphoproliferative cell disorders, such as cancer, with
 chlorotoxin and/or derivs., analogs or fragments thereof, which
 are effective to bind to an inhibitory abnormal myeloid or lymphoid cell
 growth. The chlorotoxin may be conjugated to a second protein,
 e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific
 epitope, or a stabilizing protein such as human serum albumin.
 Alternatively, the chlorotoxin may be conjugated to a cytotoxic
 agent or chemotherapeutic agent.

LS ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003197197 CAPLUS

DN 140:332:19
 TI Combination chemotherapy with chlorotoxin for treating
 cancer

IN Alvarez, Vernon L.; Grimes, Carol A.; Gonda, Matthew A.

PA Transmolecular, Inc., USA

SO PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT²

PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2003101474 A1 20031211 WO 2003-US17410 20030602
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LR,
 LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MY, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT,
 TZ, UR, US, VN, YU, ZA, ZM, RW: GH, GM, KE, LS, MN, ME, SD, SL, SZ, TZ, UG, ZH, AM, AZ, BY,
 KG, KZ, MD, RU, TU, TM, AT, BE, BG, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 CA, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TC
 AU 20031211 AA 20031211 CA 2003-248745 20030612
 EP 1553962 A1 20031219 AU 2003-240496 20030612
 R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SR
 JP 2005537234 T2 20051028 JP 2004-508829 20030602
 US 2006018899 A1 20060427 US 2005-516079 20051102
 PRAI US 2002-384171P A1 20020531 P 20020827
 WO 2003-46013P P 20030602
 AB This invention includes compns. and methods for combination
 chemotherapy, particularly involving least one
 chemotherapeutic agent used in combination with
 chlorotoxin or a derivative thereof. A method for detecting the
 presence of cancer in a patient comprising administering a detectable amount
 of labeled chlorotoxin or chlorotoxin derivative are also
 claimed.

RE.CNT³ THERE ARE 3 CITED REFERENCES AVAILABLE IN THE RE FORMAT
 LS ANSWER 3 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 AN 200227256 EMBASE
 TI Orathecin is active in pancreatic cancer patients.

SO Expert Review of Anticancer Therapy. (2002) Vol. 2, No. 2, pp. 137-140.
 ISSN: 1473-7140 CODEN: ERATBJ
 CY United Kingdom
 DT Journal; Note
 FS Cancer
 016 Biophysics, Bioengineering and Medical Instrumentation
 027 Pharmacology
 030 Drug Literature Index
 037 Adverse Reactions Titles
 038
 LA 039 Pharmacy
 English
 ED Entered STN: 11 Jul 2002
 Last Updated on STN: 11 Jul 2002
 DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
 LS ANSWER 4 OF 9 IPIPAT COPYRIGHT 2006 IFI on STN
 AN 11139883 IPIPAT;IFIIDB;IFIICDB
 TI COMBINATION CHEMOTHERAPY WITH CHLOROTOXIN
 INF Alvarez; Vernon L., Birmingham, AL, US
 Gonda; Matthew A., Birmingham, AL, US
 Grimes; Carol A., Birmingham, AL, US
 Alvarez; Vernon L.; Gonda; Matthew A.; Grimes; Carol A.
 PAF Unassigned
 PA Unassigned Or Assigned To Individual (68000)
 AG MORGAN LEWIS & BOKDINS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC,
 20004, US
 PI US 2005088899 A1 20060427
 AI US 2003-516779 20030602
 WO 2003-US17410 20051102 PCT 371 date
 20051102 PCT 102 (e) date
 PRAI US 2002-384171P (Provisional)
 US 2002-4-060333P (Provisional)
 FI US 2005088999 20050427 (Provisional)
 DT Ut-ility; Patent Application - First Publication
 PS CHEMICAL
 PARN This application claims the benefit of U.S. Provisional Application
 60/384,171 (filed May 31, 2002) both of which are hereby incorporated by
 reference in their entirety.
 CLMN 17
 OF 9 IPIPAT COPYRIGHT 2006 IFI on STN
 AB This invention includes compositions and methods for combination
 chemotherapy, particularly involving at least one
 chemotherapeutic agent used in combination with
 chlorotoxin or a derivative thereof.
 CLMN 17
 LS ANSWER 5 OF 9 PRONT COPYRIGHT 2006 Gale Group on STN
 AN 2000-824983 PRONT
 TI OTHER NEWS TO NOTE
 SO BIOWORLD TODAY (22 SEP 2000) VOL. 11, NO. 184.
 PB American Health Consultants, Inc.
 DT Newsletter
 LA English
 WC 1452 *FULL TEXT IS AVAILABLE IN THE FULL FORMAT.*
 AB Acys Pharmaceuticals Inc., of South San Francisco, said it agreed to
 sell \$26 million aggregate principal amount of 8 percent senior secured
 convertible notes maturing on Oct. 1, 2004. Acys previously announced its
 intention to sell up to \$40 million of fixed rate convertible notes. Diaz
 & Altschul Capital LLC served as placement agent for the transaction.
 THIS IS THE FULL TEXT: COPYRIGHT 2000 American Health Consultants, Inc.
 Subscription: \$1350.00 per year. Published daily (5 times a week).

LS ANSWER 6 OF 9 USPATFULL on STN
 AN 2005-244233 USPATFULL
 TI PI-3 Kinase inhibitor prodrgus
 IN Garlich, Joseph R., Westfield, IN, UNITED STATES
 Durden, Donald L., Decatur, GA, UNITED STATES
 Patterson, Mary, Carmel, CA, UNITED STATES
 Su, Jingdong, Westfield, IN, UNITED STATES
 Suhr, Robert G., Greenfield, IN, UNITED STATES
 PI US 2005203173 A1 20050915
 AI US 2005-111201 A1 20050420 (11)
 RLI Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING
 PRAI US 2005-460137P 20030403 (60)
 DT UTILITY
 FS APPLICATION
 LREP HORNEY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE
 200, FALLS CHURCH, VA, 22042-2924, US
 CLMN Number of Claims: 1
 ECL Exemplary Claim: 1
 DRWN Drawing Page(s)
 LN CNT 2848
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The
 novel compounds are LY294002 and analogs thereof comprising a reversibly
 quaternized amine.
 CLMN 1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 LS ANSWER 7 OF 9 USPATFULL on STN
 AN 2005-105793 USPATFULL
 TI Therapy via targeted delivery of nanoscale particles
 IN Ivkovic, Robert, Marblehead, MA, UNITED STATES
 Daum, Wolfgang, Groton, MA, UNITED STATES
 Foreman, Allan, Epping, NH, UNITED STATES
 Gwest, Douglas, Shoreview, MN, UNITED STATES
 PA Triton Biosystems, Inc., Chatsworth, CA, UNITED STATES (U.S.
 corporation)
 PI US 2005090732 A1 20050428
 AI US 2003-636399 A1 20031028 (10)
 DT UTILITY
 FS APPLICATION
 LREP PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET,
 PITTSBURGH, PA, 15219, US
 CLMN Number of Claims: 110
 ECL Exemplary Claim: 1
 DRWN 12 Drawing Page(s)
 LN CNT 2898
 AB Disclosed are compositions, systems and methods for treating a subject's
 body, body part, tissue, body fluid cells, pathogens, or other
 undesirable matter involving the administration of a targeted
 thermotherapy that comprises a bioprobe (energy susceptive materials
 that are attached to a target-specific ligand). Such targeted therapy
 methods can be combined with at least one other therapy technique. Other
 therapies include hyperthermia, direct antibody therapy, radiation,
 chemo- or pharmaceutical therapy, photodynamic therapy, surgical or
 interventional therapy, bone marrow or stem cell transplantation, and
 medical imaging, such as MRI, PET, SPECT, and bioimaging. The
 disclosed therapies may be useful in the treatment of a variety of
 indications, including but not limited to, cancer of any type, such as
 bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate
 cancer, epithelialoid sarcomas, AIDS, adverse angiogenesis, resenosis,
 amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque,
 obesity, malaria, and illnesses due to viruses, such as HIV.

LS ANSWER 8 OF 9 USPATFULL on STN
 AN 2004-307955 USPATFULL
 TI PI-3 Kinase inhibitor prodrgus
 IN Garlich, Joseph R., Westfield, IN, UNITED STATES
 Durden, Donald L., Decatur, GA, UNITED STATES

Patterson, Mary, Carmel, IN, UNITED STATES
 Su, Jingdong, Westfield, IN, UNITED STATES
 Subr, Robert G., Greenfield, IN, UNITED STATES
 PI US 200424631 AI 20041202
 US 6949537 B2 20050927
 AI US 2004-818145 AI 20040405 (10)
 PRAI DT UTILITY
 FS APPLICATION
 LREP HORRY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34,
 1229 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402
 CLAN Number of Claims: 40
 ECL Exemplary Claim: 1
 DRNN 8 Drawing Page(s)
 LN CNT 3032
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The
 novel compounds are LY294002 and analogs thereof comprising a reversibly
 quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 9 USPATFULL on STN
 AN 2004-197463 USPATFULL
 TI Modified carbamate-containing prodrugs and methods of synthesizing same
 IN Eksourbe, Nnochiri Nkem, Cary, NC, UNITED STATES
 Riegs-Sauvher, Jennifer, Raleigh, NC, UNITED STATES
 Dyakonov, Tatyana A., Durham, NC, UNITED STATES
 PI US 2004152769 AI 20040805
 US 2003-703647 AI 20031107 (10)
 PRAI US 2002-424796P 20021109 (60)
 US 2003-433676P 20030630 (60)
 DT UTILITY
 FS APPLICATION
 LREP MYERS BIGEL SIBLEY & SABOVC, PO BOX 37428, RALEIGH, NC, 27627
 CLAN Number of Claims: 51
 ECL Exemplary Claim: 1
 DRNN 5 Drawing Page(s)
 LN CNT 2938
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Prodrugs having a hydrolyzable carbamate moiety, compositions including
 the prodrugs, methods of preparing the prodrugs and methods of treatment
 using the prodrugs are disclosed. The prodrug has the formula DC(X)R,
 where D is biologically active agent, X is O, S or NR¹, and R is a
 moiety that modifies various properties of the biologically active
 agent. The biologically active agent either includes a functional group
 such as an amide, thioamide, imide, thioimide, urea, thiourea,
 carbamate, thiocarbamate, sulfonamide, or thiol group that is modified to
 include such a group. An NH group from the biologically active agent can
 be coupled to an activated form of the C(X)R moiety to form the prodrugs
 described herein. Relative to a conventional carbamate group, the
 presence of the additional carbonyl or sulfonyl group makes the
 carbamate group more susceptible to hydrolysis. The prodrugs are more
 stable in certain environments than the biologically active agent, and
 can permit the drugs to be administered orally, in those embodiments
 where the biologically active agent must otherwise be administered by
 injection or intravenous administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOMS' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISICTI', 'ADISINSIGHT', 'ADISNEWS', 'AGRICOLA', 'ANABSTR', 'ANTE', 'AQUALINE',
 'AQUASCII', 'BIOENG', 'BIOSIS', 'BIOTECHABS', 'BIOTECHDS', 'BIOTECNO', 'CABA', 'CAPLUS',
 'CEABA-VTB', 'CIN', 'CONFSCI', 'CROPP', 'DDFB', 'DGENE', 'DISSABS', 'DRUGB',
 'EMLIST', 'EMBASE', 'ESBIOBASE', 'IFIPAT', 'MEDLINE', 'PRMT', 'TOXCENTER', 'USPATFULL', 'WPINDEX'

DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006

SEA CHLOROTOXIN

 3 FILE ADISINSIGHT
 5 FILE AGRICOLA
 5 FILE ANABSTR
 1 FILE BIOSIS
 32 FILE BIOTECHABS
 3 FILE BIOTECHDS
 3 FILE BIOTECHS
 8 FILE BIOTECHNO
 11 FILE CABA
 41 FILE CAPLUS
 1 FILE CEABA-VTB
 8 FILE CTN
 2 FILE DDFU
 235 FILE DGENE
 2 FILE DISABS
 2 FILE DRUGU
 28 FILE EMBASE
 22 FILE ESBIOBASE
 1 FILE GENBANK
 13 FILE IFIPAT
 9 FILE IMSDRUGNEWS
 5 FILE IMSEARCH
 13 FILE LIFESECI
 13 FILE MEDLINE
 31 FILE PASCAL
 17 FILE PHAR
 5 FILE PHIN
 29 FILE PRONT
 38 FILE SCISEARCH
 68 FILE TOXCENTER
 38 FILE USPATFULL
 7 FILE USPAT2
 11 FILE WPIDS
 11 FILE WINDEX
 QUE CHLOROTOXIN

 SEA LI AND CHEMOTHER?

L1 -----
 1 FILE ADISINSIGHT
 1 FILE BIOTECHNO
 2 FILE CAPLUS
 129 FILE DGENE
 2 FILE EMBASE
 2 FILE ESBIOBASE
 1 FILE IFIPAT
 1 FILE IMSDRUGNEWS
 1 FILE IMSEARCH
 1 FILE MEDLINE
 2 FILE PHAR
 1 FILE PHIN
 11 FILE PRONT
 3 FILE TOXCENTER
 16 FILE USPATFULL
 4 FILE USPAT2
 2 FILE WPIDS
 2 FILE WINDEX
 QUE LI AND CHEMOTHER?

L2 -----
 FILE 'DGENE', 'CAPLUS', 'BIOTECHNO', 'EMBASE', 'ESBIOBASE', 'IFIPAT', 'MEDLINE',
 'PRONT', 'TOXCENTER', 'USPATFULL', 'WPINDEX' ENTERED AT 03:12:00 ON 09

JUN 2006
 L3 174 S L2
 L4 163 DUP REMO L3 (11 DUPLICATES REMOVED)
 L5 9 S L4 AND (BENZ OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR P
 L6 13 S L4 AND (CIPLATIN OR METHOTREXATE OR MERCAPTOPURINE OR THIOGU
 L7 13 S L4 AND (DOCEPAZEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOM

L8 7 S L4 AND (ANASTROZOLE OR AMEACRINE OR ASPARAGINASE OR MITOXANT
L9 6 S L5 AND L6 AND L7 AND L8

=> d 16 1-13 bib abs

L6 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

AN 143:41320 CAPLUS

DN 143:41320 CAPLUS

TI Use of chlorotoxin in diagnosis and treatment of myeloid and lymphoid cell cancers

IN Alvarez, Vernon L.; Gonda, Matthew A.

PA Transmolecular, Inc., USA

SO PCT Int. Appl., 52 pp.

DT Patent

LA English

FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200509774	A2	20051027	WO 2005-US11523	20050406
WO 200509774	A3	20060123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, RW, GM, KE, LS, MW, MZ, NA, SD, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, ML, MR, NE, SN, TD, TG	PRAI US 2004-55433P	P 20040406		

AB Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivs., analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth. The chlorotoxin may be conjugated to a second protein, e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific epitope, or a stabilizing protein such as human serum albumin. Alternatively, the chlorotoxin may be conjugated to a cytotoxic agent or chemotherapeutic agent.

L6 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

AN 140:23219 CAPLUS

TI Combination chemotherapy with chlorotoxin for treating cancer

IN Alvarez, Vernon L.; Grimes, Carol A.; Gonda, Matthew A.

PA Transmolecular, Inc., USA

SO PCT Int. Appl., 100 pp.

DT Patent

LA English

FAN CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101474	A1	20031211	WO 2003-US17410	20031602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GM, HR, HU, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, MA, MD, MG, MN, MW, MX, NA, NI, NO, NZ, OM, PH, PL, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, ML, MR, NE, SN, TD, TG	PRAI US 2003-384171P	P 20030403		

AB This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled chlorotoxin or chlorotoxin derivative are also claimed.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE IN THE RE FORMAT

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 13 IFIPAT COPYRIGHT 2006 IFI on STN

AN 1113983; IFIPAT;IFICDB;IFIICDB

TI COMBINATION CHEMOTHERAPY WITH CHLOROTOXIN

INF Alvarez, Vernon L., Birmingham, AL, US

Gonda, Matthew A., Birmingham, AL, US

Grimes, Carol A., Birmingham, AL, US

IN Alvarez, Vernon L.; Gonda, Matthew A.; Grimes, Carol A.

PAF Unassigned

PA Unassigned Or Assigned To Individual (68000)

AG MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC,

PI PI 0004, US

PI PI 20060427

AI AI 20030602

WO 2003-US17410 20030602

PCT 371 date 20051102

PCT 102 (e) date 20051102

(Provisional) 20020531

(Provisional) 20020827

(Provisional) 20060427

APPLICATION

PARN This application claims the benefit of U.S. Provisional Application 60/406,033 (filed Aug. 27, 2002) and U.S. Provisional Application 60/384,171 (filed May 31, 2002) both of which are hereby incorporated by reference in their entirety.

CLMN 17

OF 13 IFIPAT COPYRIGHT 2006 IFI on STN

AB This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

CLMN 17

OF 13 IFIPAT COPYRIGHT 2006 IFI on STN

AB This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

CLMN 17

ANSWER 4 OF 13 USPATFOLL on STN

AN 2005:234233 USPATFOLL

TI PI-3 kinase inhibitor prodrgs

IN Garlich, Joseph R., Westfield, IN, UNITED STATES

Durden, Donald L., Decatur, GA, UNITED STATES

Patterson, Mary, Carmel, GA, UNITED STATES

Su, Jingdong, Westfield, IN, UNITED STATES

Suh, Robert G., Greenfield, IN, UNITED STATES

PI US 2005-203173 AI 2005-0915

US 2005-111201 AI 2005-0420 (11)

RJL Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING

PRAI US 2003-460137P 20030403 (60)

DT UTILITY

FS APPLICATION

LREP HONEY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE

CLMN Number of Claims: 1
 ECL Exemplary Claim: 1
 DRWN Drawing Page(s) 18
 LN.CNT 2848
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 13 USPATFULL ON STN
 AN 2005:215483 USPATFULL
 TI Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

IN Bridon, Dominique P., Ville Mont-Royal, CANADA
 Ezrin, Alan M., Morga, CA, UNITED STATES
 Milner, Peter G., Los Altos, CA, UNITED STATES
 Holmes, Darren L., Montreal, CANADA
 Thibaudeau, Karen, Montreal, CANADA
 ConjuChem, Inc., Montreal, CANADA (non-U.S. corporation)

PA US 2005187159 AI 20050825 (11)
 PI US 2005-66697 AI 20050225 (11)
 RLI Continuation of Ser. No. US 2000-657276, filed on 7 Sep 2000, GRANTED.
 Pat. No. US 6887470

PRAI US 1999-153406P 19990910 (60)
 US 1999-153783P 19991015 (60)

DT UTILITY

FS APPLICATION MORRISON & FOERSTER LLP, 425 MARKET STREET, SAN FRANCISCO, CA, 94105-2482, US

CLMN Number of Claims: 29
 ECL Exemplary Claim: 1-26
 DRWN No Drawings
 LN.CNT 5233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 13 USPATFULL ON STN
 AN 2005:107237 USPATFULL
 TI Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

IN Bridon, Dominique P., Ville Mont-Royal, CANADA
 Ezrin, Alan M., Morga, CA, UNITED STATES
 Milner, Peter G., Los Altos, CA, UNITED STATES
 Holmes, Darren L., Montreal, CANADA
 Thibaudeau, Karen, Montreal, CANADA
 ConjuChem, Inc., Montreal, CANADA (non-U.S. corporation)

PA US 6887470 B1 20050503 (9)
 PI US 2000-557226 20000907 (9)
 PRAI US 1999-153703P 19991015 (60)
 US 1999-153406P 19990910 (60)

DT UTILITY
 FS GRANTED
 EXAM Primary Examiner: Weber, Jon; Assistant Examiner: Snedden, Sheridan
 LREP Morrison & Foerster LLP
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 5136
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 13 USPATFULL ON STN
 AN 2005:105793 USPATFULL
 TI Therapy via targeted delivery of nanoscale particles
 IN Ivkoy, Robert, Marblehead, MA, UNITED STATES
 Daum, Wolfgang, Groton, MA, UNITED STATES
 Foreman, Allan, Epping, NH, UNITED STATES
 Gwozdz, Douglas, Shoreview, MN, UNITED STATES
 PA Triton Biosystems, Inc., Chelmsford, MA, UNITED STATES (U.S. corporation)
 PI US 2003090732 A1 20050426 (10)
 AI US 2003-686399 A1 20031028 (10)

DT UTILITY
 FS APPLICATION PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET, PITTSBURGH, PA, 15219, US

CLMN Number of Claims: 110
 ECL Exemplary Claim: 1
 DRWN 12 Drawing Page(s)
 LN.CNT 2898

AB Disclosed are compositions, systems and methods for treating a subject's undesirable matter involving the administration of a targeted thermotherapy that comprises bioprobe (energy susceptive materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epithelioid sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 13 USPATFULL ON STN
 AN 2005:23381 USPATFULL
 TI Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

IN Bridon, Dominique P., Outremont, CANADA
 PA US 6887470 B1 20050503 (9)
 PI US 2000-557226 20000907 (9)
 PRAI US 1999-153703P 19991015 (60)
 US 1999-153406P 19990910 (60)

Ezzin, Alan M., Moraga, CA, United States
Malner, Peter G., Los Altos Hills, CA, United States
Holmes, Darren L., Montreal, Canada
Thibaudeau, Karen, Montreal, Canada
ConjuChem, Inc., Montreal, Canada (non-U.S. corporation)
US 6849714 B1 20050201
WO 2000065900 200001123
US 2000-633548 20000905 (9)
WO 2000-13576 20000517

PRAI US 1999-134406P 19990517 (60)
US 1999-153406P 19990910 (60)
US 1999-159783P 19991015 (60)

DT UTILITY

FS GRANTED

Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Desai, Anand

LREP Morrison & Foerster LLP

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRAWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN CNT 5160

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide having between 3 and 50 amino acids is k. In a first step of the method, a therapeutic peptide having a carboxy terminal amino acid and amino terminal acid is synthesized. In a second step, pairs of cysteine residues present in the therapeutic peptide are sequentially and selectively oxidized to form disulfide bridges in the therapeutic peptide. In a third step, a protecting group is attached to remaining cysteine residues that do not form disulfide bridges in the therapeutic peptide. Finally, the peptide is coupled to a reactive group capable of reacting with amino groups, hydroxyl groups or thiol groups on a blood component to form a covalent bond therewith.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 13 USPATFULL ON STN

AN 2004-307955 USPATFULL

TI PI-3 kinase inhibitor prodrugs

IN IN Garlich, Joseph R., Westfield, IN, UNITED STATES

Durden, Donald L., Decatur, GA, UNITED STATES

Patterson, Mary, Carmel, IN, UNITED STATES

Su, Jingdong, Westfield, IN, UNITED STATES

Suhr, Robert G., Greenwood, IN, UNITED STATES

PI US 200422631 A1 20041202

US 6949537 B2 20050927

US 2004-1818145 A1 20040405 (10)

US 2003-460137P 20030303 (60)

DT UTILITY

FS APPLICATION

LREP HOWREY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34,

1299 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRAWN 8 Drawing Figure(s)

LN CNT 3032

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 13 USPATFULL ON STN

AN 2004-19763 USPATFULL

TI Modified carbamate-containing prodrugs and methods of synthesizing same

IN Ekwuribe, Nnochiri Nkem, Cary, NC, UNITED STATES

Riggs-Sauthier, Jennifer, Raleigh, NC, UNITED STATES

Dyakonov, Tatjana A., Durham, NC, UNITED STATES

PI US 2004-152169 A1 2003-0805

AI US 2003-703647 A1 2003-1107

PRAI US 2002-424796P 2002-1109

US 2003-483676P 2003-0630

DT UTILITY

FS APPLICATION

LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627

CLMN Number of Claims: 51

ECL Exemplary Claim: 1

DRAWN 5 Drawing Page(s)

LN CNT 2938

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Prodrugs having a hydrolyzable carbamate moiety, compositions including the prodrugs, methods of preparing the prodrugs and methods of treatment using the prodrugs are disclosed. The prodrug has the formula DC(X)XR, where D is a biologically active agent, X is O, S or NR, and R is a moiety that modifies various properties of the biologically active agent. The biologically active agent either includes a functional group such as an amide, thioamide, imide, thiourea, urea, thiourea, carbamate, thiocarbamate, sulfonamide, or sulfonylurea group, or includes a hydroxy, amine, carboxylic acid or thiol group that is modified to include such a group. An NH group from the biologically active agent can be coupled to an activated group from the C(X)XR moiety to form the prodrugs described herein. Relative to a conventional carbamate group, the presence of the additional carbonyl or sulfonyl group makes the carbamate group more susceptible to hydrolysis. The prodrugs are more stable in certain environments than the biologically active agent, and can permit the drugs to be administered orally, in those embodiments where the biologically active agent must otherwise be administered by injection or intravenous administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 13 USPATFULL ON STN

AN 2004-23553 USPATFULL

TI Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith

IN Soister, Richard, Holly Springs, NC, UNITED STATES

Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES

Opawale, Foyeku, Raleigh, NC, UNITED STATES

Rehlaender, Bruce, Chapel Hill, NC, UNITED STATES

Hickey, Anthony, Chapel Hill, NC, UNITED STATES

Bovet, Li Li, Chapel Hill, NC, UNITED STATES

PI US 2004-017387 A1 2004-04-19

US 703082 B2 2006-04-18

AI US 2003-312069 A1 2003-03-05 (10)

RJ1 Continuation-in-part of Ser. No. US 2002-235281, filed on 5 Sep 2002,

PENDING Continuation-in-part of Ser. No. US 2002-235284, filed on 5 Sep 2002, PENDING

PRAI US 2001-318193P 2001-0907 (60)

DT UTILITY

FS APPLICATION

LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627

CLMN Number of Claims: 80

ECL Exemplary Claim: 1

DRAWN 19 Drawing Page(s)

LN CNT 3722

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1 or any value between. Methods of treating diseases in a subject of need of such treatment using the pharmaceutical compositions of this invention are also

provided, as well as methods of providing such pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 13 USPATFULL ON STN
AN 2003:306886 USPATFULL
TI Peptides for recognition and targeting of GLIAL cell tumors
IN Samoilova, Tatiana I., Auburn, AL, UNITED STATES
Petrenko, Valery A., Auburn, AL, UNITED STATES
Cox, Nancy R., Auburn, AL, UNITED STATES
Morrison, Nancy E., Auburn, AL, UNITED STATES
Baker, Henry J., Auburn, AL, UNITED STATES
Globa, Ludmila P., Auburn, AL, UNITED STATES
Auburn University (U.S. corporation)
US 2003216322 AI 200301120
US 2003-357929 AI 20030304 (10)
PRAI DT 20020204 (60)
Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 20
ECLN Exemplary Claim: 1
DRAWN 11 Drawing Page(s)
LN CNT 1835

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions for use in characterization, diagnosis, prognosis, and therapy of cancer cells are provided. The compositions comprise peptides and variants thereof which were isolated based on their ability to selectively bind glioma cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

16 ANSWER 13 OF 13 USPATFULL ON STN
AN 2003:10050 USPATFULL
TI Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
IN Soltero, Richard, Holly Springs, NC, UNITED STATES
Bkouribe, Nnochiri N., Cary, NC, UNITED STATES
Opawale, Foyeke, Raleigh, NC, UNITED STATES
Rehlander, Bruce, Chapel Hill, NC, UNITED STATES
Hickey, Anthony, Chapel Hill, NC, UNITED STATES
LI Li, Bovet, Chapel Hill, NC, UNITED STATES
US 2003059170 AI 200304010
US 6770625 B2 20040803
AI US 2002-235284 AI 20000905 (10)
PRAI US 2001-18193P 20010907 (60)
US 2002-377865P 2002020503 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGAL SIBILY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 130
ECLN Exemplary Claim: 1
DRAWN 13 Drawing Page(s)
LN CNT 3615

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOTENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFCI, CROPU, CROPU, DDFU, DDFU, DSISSA, DRUGS, DRUGMONO2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006

3 FILE ADISINSIGHT

5 FILE AGRICOLA

1 FILE ANABSTR

32 FILE BIOSIS

3 FILE BIOTECHABS

3 FILE BIOTECHDS

8 FILE BIOTECHNO

11 FILE CABA

41 FILE CAPLUS

1 FILE CEABA-VTB

8 FILE CIN

2 FILE DDFU

235 FILE DGENE

2 FILE DISABS

2 FILE DRUGU

28 FILE EMBASE

22 FILE ESBIOLBASE

1 FILE GENBANK

13 FILE IFPAT

9 FILE IMDRUGNEWS

5 FILE IMRESEARCH

13 FILE LIFSCI

31 FILE MEDLINE

17 FILE PASCAL

5 FILE PHAR

5 FILE PHIN

29 FILE PRONT

38 FILE SCISearch

68 FILE TOXCENTER

38 FILE USPATFULL

7 FILE USPAT2

11 FILE WPIDS

11 FILE WPINDEX

QUE CHLOROTOXIN

SEA L1 AND CHEMOTHER?

1 FILE ADISINSIGHT

1 FILE BIOTECHNO

1 FILE CAPLUS

129 FILE DGENE

2 FILE EMBASE

2 FILE ESBIOLBASE

1 FILE IFPAT

1 FILE IMDRUGNEWS

1 FILE IMRESEARCH

1 FILE MEDLINE

2 FILE PHAR

1 FILE PHIN

11 FILE PRONT

3 FILE TOXCENTER

16 FILE USPATFULL

4 FILE USPAT2

2 FILE WPIDS

2 FILE WPINDEX

QUE L1 AND CHEMOTHER?

FILE 'DGENE, CAPLUS, BIOTECHNO, EMBASE, ESBIOLBASE, IFPAT, MEDLINE, PRONT, TOXCENTER, USPATFULL, USPAT2, WPINDEX' ENTERED AT 03:12:00 ON 09

JUN 2006

L3 174 S L2
L4 163 DUP REMO L3 (11 DUPLICATES REMOVED)
L5 9 S L4 AND (BCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR P
L6 13 S L4 AND (CIPPLATIN OR MERCAPTOPURINE OR MERCAPTOREXATE OR THIOGU
L7 13 S L4 AND (DOCETAZEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOM
L8 7 S L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARGINASE OR MITOXANT
L9 6 S L5 AND L6 AND L7 AND L8